Cellectis S.A. Stock price

Equities

ALCLS

FR0010425595

Biotechnology & Medical Research

Market Closed - Euronext Paris 12:35:17 2024-03-18 pm EDT 5-day change 1st Jan Change
2.3 EUR -1.63% Intraday chart for Cellectis S.A. -3.60% -16.79%
Sales 2023 * 21.51M 23.38M Sales 2024 * 27.32M 29.7M Capitalization 165M 179M
Net income 2023 * -69M -75.02M Net income 2024 * -69M -75.02M EV / Sales 2023 * 4.21 x
Net cash position 2023 * 74.53M 81.03M Net cash position 2024 * 18.69M 20.32M EV / Sales 2024 * 5.36 x
P/E ratio 2023 *
-
P/E ratio 2024 *
-
Employees 234
Yield 2023 *
-
Yield 2024 *
-
Free-Float 100%
More Fundamentals * Assessed data
Dynamic Chart
European Equities Traded in the US as American Depositary Receipts Trend Higher in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Open Week Lower in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading MT
European Equities Traded in the US as American Depositary Receipts Open Week Flat in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Rise Friday, Set to End Week Up 1.5% MT
European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading MT
European Equities Traded in the US as American Depositary Receipts Start Week Lower in Monday Trading MT
AstraZeneca: $300 million invested in the USA CF
European Equities Traded in the US as American Depositary Receipts Trend Lower in Monday Trading MT
European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading, End Week Up 2.6% MT
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading MT
Cellectis: second tranche of EIB loan drawn down CF
Cellectis Draws Down EUR15 Million Tranche Under European Investment Bank Credit Facility MT
Cellectis Announces the Drawdown of the Second Tranche of 15 Million Under the Credit Facility Agreement Entered with the European Investment Bank CI
European Equities Traded in the US as American Depositary Receipts Trend Modestly Higher in Wednesday Trading MT
More news
1 day-1.63%
1 week-6.20%
Current month+1.05%
1 month-10.51%
3 months-17.86%
6 months+47.06%
Current year-16.79%
More quotes
1 week
2.28
Extreme 2.278
2.45
1 month
2.17
Extreme 2.166
2.64
Current year
2.17
Extreme 2.166
2.88
1 year
0.89
Extreme 0.888
3.44
3 years
0.89
Extreme 0.888
18.24
5 years
0.89
Extreme 0.888
28.45
10 years
0.89
Extreme 0.888
41.95
More quotes
Managers TitleAgeSince
Founder 57 99-12-19
Founder 59 99-12-19
Director of Finance/CFO 47 22-02-09
Members of the board TitleAgeSince
Chairman 75 20-11-04
Founder 59 99-12-19
Founder 57 99-12-19
More insiders
Date Price Change Volume
24-03-18 2.3 -1.63% 37,661
24-03-15 2.338 -0.51% 22,264
24-03-14 2.35 -1.18% 38,069
24-03-13 2.378 -1.65% 26,877
24-03-12 2.418 +1.34% 22,610

Real-time Euronext Paris, March 18, 2024 at 12:35 pm EDT

More quotes
Cellectis S.A. is a clinical-stage biotechnology company using its pioneering TALEN® genome-editing technology to develop innovative therapies for the treatment of serious diseases. Cellectis S.A. is developing the first CAR-T cell-based allogeneic immunotherapy therapeutics, inventing the concept of off-the-shelf, ready-to-use engineered CAR-T cells for the treatment of cancer patients, and a platform for performing therapeutic genetic modifications in hematopoietic stem cells in a various diseases. Capitalizing on its 23 years of expertise in genome engineering, its TALEN® genome editing technology and its pioneering PulseAgile electroporation technology, Cellectis S.A. is developing innovative product candidates using the power of the immune system to treat diseases with unmet medical needs. As part of its commitment to the search for curative cancer therapies, Cellectis S.A. is developing UCART product candidates directed at the unmet medical needs of patients with certain types of cancer, including acute myeloid leukemia, B-cell acute lymphoblastic leukemia, and multiple myeloma. HEAL is a new platform focused on hematopoietic stem cells for the treatment of blood disorders, immune deficiencies, and lysosomal storage diseases.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Quarterly revenue - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Cellectis S.A. - Euronext Paris